Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.

Doi, Kent; Ikeda, Mahoko; Hayase, Naoki; Moriya, Kyoji; Morimura, Naoto

Doi, Kent; Ikeda, Mahoko; Hayase, Naoki; Moriya, Kyoji; Morimura, Naoto.

Doi K; Department of Acute Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan. kdoi-tky@umin.ac.jp.
Ikeda M; Department of Infection Control and Prevention, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Hayase N; Department of Acute Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Moriya K; Department of Infection Control and Prevention, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Morimura N; Department of Infectious Diseases, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.

Crit Care ; 24(1): 392, 2020 07 03.

Article in English | MEDLINE | ID: covidwho-631375

Subject(s)

Amides/therapeutic use; Guanidines/therapeutic use; Pyrazines/therapeutic use; Aged; Benzamidines; Coronavirus Infections/drug therapy; Critical Illness; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Treatment Outcome; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pyrazines / Amides / Guanidines Type of study: Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: Crit Care Year: 2020 Document Type: Article Affiliation country: S13054-020-03078-z

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google